Stocks · News reference
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.